z-logo
open-access-imgOpen Access
Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis
Author(s) -
Tarek M Elghandour,
Sahar El Sayed Youssef,
Dalia Gamal Aly,
Mohamed Said Abd Elhameed,
Mehrevan Mostafa Abdel Moneim
Publication year - 2013
Publication title -
dermatology research and practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.456
H-Index - 29
eISSN - 1687-6113
pISSN - 1687-6105
DOI - 10.1155/2013/618269
Subject(s) - medicine , psoriasis , ultraviolet b , methotrexate , interleukin 23 , interleukin , interleukin 17 , interleukin 4 , immunology , gastroenterology , dermatology , inflammation , cytokine
Background . There is raised interest in the involvement of interleukin-(IL-)23/T-helper 17 cells (Th17) axis in the pathogenesis of psoriasis. Objectives . To compare the effect of narrow band ultraviolet B (NB-UVB) and methotrexate (MTX) therapy on serum levels of IL-17 and IL-23 in psoriatic patients. Methods . Thirty patients with severe plaque psoriasis were included: 15 patients received NB-UVB three times weekly (group I) and 15 patients received MTX 0.3 mg/kg per week (group II), both for 8 weeks. Before and after treatment, serum levels of IL-17 and IL-23 were investigated by ELISA technique and psoriasis area and severity index (PASI) was calculated. Results . After treatment, all patients showed a reduction in their PASI score, IL-17 and IL-23 serum levels with a nonsignificant difference between both therapeutic modalities ( P value >0.05). A positive correlation was detected between the percent of reduction of IL-17, IL-23 and the percent of reduction of PASI score for patients receiving both treatments. No correlation was found between the percent of reduction of IL-17, IL-23 and duration of disease or age of all patients in this study. Conclusion . Interleukin-17 and IL-23 serum level may serve as a potential biomarker for predicting the prognosis and therapeutic response of NB-UVB or MTX in treating psoriasis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom